Radius Health, Inc. (NASDAQ:RDUS) VP Brent Hatzis-Schoch bought 1,778 shares of Radius Health stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $28.09 per share, with a total value of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares in the company, valued at approximately $63,989.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Radius Health, Inc. (NASDAQ:RDUS) traded down $0.16 on Monday, hitting $27.94. The company had a trading volume of 1,116,709 shares, compared to its average volume of 961,724. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health, Inc. has a one year low of $27.16 and a one year high of $55.97.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. equities research analysts predict that Radius Health, Inc. will post -5.4 EPS for the current fiscal year.
A number of research firms have commented on RDUS. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group LLC reduced their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $51.00.
Several institutional investors and hedge funds have recently modified their holdings of RDUS. Sei Investments Co. grew its holdings in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 690 shares during the period. Ameritas Investment Partners Inc. lifted its position in Radius Health by 19.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. lifted its position in Radius Health by 267.2% during the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Blair William & Co. IL purchased a new position in Radius Health during the second quarter valued at $205,000. Finally, Amalgamated Bank purchased a new position in Radius Health during the second quarter valued at $211,000.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.